Is CG Oncology, Inc. (CGON) Overvalued?
We dive into why CG Oncology, Inc. (CGON) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
Commentary & Analysis
What You Need to Know About CG Oncology, Inc.'s Q3 Earnings
CG Oncology, Inc.'s fiscal Q3 earnings report was released on Thursday, August 06. Let's dive in to see if (CGON) missed or beat analyst's expectations.Michael Rose
Why CG Oncology, Inc.’s (CGON) Stock Is Down 6.24%
As of Wednesday, July 29, CG Oncology, Inc.’s CGON share price has dipped by 6.24%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why CG Oncology, Inc.’s (CGON) Stock Is Up 5.11%
As of Thursday, July 23, CG Oncology, Inc.’s CGON share price has surged by 5.11%, which has investors questioning if this is right time to sell.Jenna Brashear
Why CG Oncology, Inc.’s (CGON) Stock Is Down 5.47%
As of Thursday, July 16, CG Oncology, Inc.’s CGON share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CGON | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,951.2 | $298.4 | 72% |
|
| Shares Out (Mil) | 88.2 | 54.0 | 60% |
|
| Institutional Ownership | 99.0% | 93.1% | 84% |
|
| Float (Mil) | 64.7 | 41.4 | 53% |
|
| Beta | 0.23 | 0.94 | 14% |
|
| Avg Daily Volume (000s) | 749 | 504 | 66% |
|
| Price Change (52-week) |
208.5% | 62.0% | 97% |
|
| Growth | CGON | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | na | (10.0%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 13 | 12 | |
| Current EPS | ($0.810) | ($3.205) | ($3.021) | |
| Month Ago EPS | ($0.680) | ($2.671) | ($2.749) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 3 | |
| Three Months Ago EPS | ($0.667) | ($2.655) | ($2.779) | |
| Year/Year Chg | (9.6%) | 53.9% | (52.4%) | |
| Financials | CGON | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6 | $37 | 7% |
|
| Net Income (TTM) (Mil) | ($224) | ($43) | 6% |
|
| EPS (TTM) | ($2.724) | ($1.400) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($179) | ($32) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $2 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $8 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $6,055 | $186 | 65% |
|
| Valuation | CGON | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.73 | 2.89 | 84% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CGON | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.6% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (25.1%) | (47.6%) | 18% |
|
| ROE | (26.4%) | (55.0%) | 21% |
|
| Liabilities to Assets | 5.2% | 29.5% | 2% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 8/26/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.9% |
| +/- S&P 500: | -4.6 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
